Base de dados : MEDLINE
Pesquisa : D27.505.519.914 [Categoria DeCS]
Referências encontradas : 31 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 31 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28886926
[Au] Autor:Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
[Ti] Título:2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
[So] Source:J Am Coll Cardiol;70(14):1785-1822, 2017 Oct 03.
[Is] ISSN:1558-3597
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk. Since the publication of that document, additional evidence and perspectives have emerged from randomized clinical trials and other sources, particularly considering the longer-term efficacy and safety of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in secondary prevention of ASCVD. Most notably, the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial and SPIRE-1 and -2 (Studies of PCSK9 Inhibition and the Reduction of Vascular Events), assessing evolocumab and bococizumab, respectively, have published final results of cardiovascular outcomes trials in patients with clinical ASCVD and in a smaller number of high-risk primary prevention patients. In addition, further evidence on the types of patients most likely to benefit from the use of ezetimibe in addition to statin therapy after acute coronary syndrome has been published. Based on results from these important analyses, the ECDP writing committee judged that it would be desirable to provide a focused update to help guide clinicians more clearly on decision making regarding the use of ezetimibe and PCSK9 inhibitors in patients with clinical ASCVD with or without comorbidities. In the following summary table, changes from the 2016 ECDP to the 2017 ECDP Focused Update are highlighted, and a brief rationale is provided. The content of the full document has been changed accordingly, with more extensive and detailed guidance regarding decision making provided both in the text and in the updated algorithms. Revised recommendations are provided for patients with clinical ASCVD with or without comorbidities on statin therapy for secondary prevention. The ECDP writing committee judged that these new data did not warrant changes to the decision pathways and algorithms regarding the use of ezetimibe or PCSK9 inhibitors in primary prevention patients with LDL-C <190 mg/dL with or without diabetes mellitus or patients without ASCVD and LDL-C ≥190 mg/dL not due to secondary causes. Based on feedback and further deliberation, the ECDP writing committee down-graded recommendations regarding bile acid sequestrant use, recommending bile acid sequestrants only as optional secondary agents for consideration in patients intolerant to ezetimibe. For clarification, the writing committee has also included new information on diagnostic categories of heterozygous and homozygous familial hypercholesterolemia, based on clinical criteria with and without genetic testing. Other changes to the original document were kept to a minimum to provide consistent guidance to clinicians, unless there was a compelling reason or new evidence, in which case justification is provided.
[Mh] Termos MeSH primário: Anticolesterolemiantes/farmacologia
Cardiologia/métodos
Doença da Artéria Coronariana/prevenção & controle
Ezetimiba/farmacologia
Hipercolesterolemia/tratamento farmacológico
Conduta do Tratamento Medicamentoso/organização & administração
[Mh] Termos MeSH secundário: Quimioprevenção/métodos
LDL-Colesterol/análise
Consenso
Inibidores Enzimáticos/farmacologia
Seres Humanos
Hipercolesterolemia/diagnóstico
Sequestrantes/farmacologia
Estados Unidos
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Cholesterol, LDL); 0 (Enzyme Inhibitors); 0 (Sequestering Agents); EOR26LQQ24 (Ezetimibe)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170910
[St] Status:MEDLINE


  2 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28169559
[Au] Autor:Gonzalez RS; Lagana SM; Szeto O; Arnold CA
[Ti] Título:Challenges in Diagnosing Medication Resins in Surgical Pathology Specimens: A Crystal-Clear Review Guide.
[So] Source:Arch Pathol Lab Med;141(9):1276-1282, 2017 Sep.
[Is] ISSN:1543-2165
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONTEXT: - Medication resins, including Kayexalate, sevelamer, and bile acid sequestrants, can be encountered in gastrointestinal tract specimens. Their classic histologic appearances have been well documented, but pathologist recognition of the resins is 75%, patient history is not always available, and atypical morphologic findings are sometimes present. OBJECTIVE: - To offer a succinct overview of resins in the gastrointestinal tract, including typical and atypical appearances, in order to serve as a quick reference guide. DATA SOURCES: - The study comprises published literature, survey data, and our personal experiences. CONCLUSIONS: - Classic morphology is the benchmark for identifying these resins, but color, location, and fish scale pattern can deviate from the norm, making proper identification a challenge. Patient history should be sought whenever possible, and ancillary staining is an option when necessary. Additionally, the presence of resins should prompt the pathologist to search for potentially related diagnoses (namely, causes of diarrhea in patients on bile acid sequestrants and diagnoses associated with renal failure in patients on Kayexalate or sevelamer).
[Mh] Termos MeSH primário: Resinas de Troca de Cátion/efeitos adversos
Trato Gastrointestinal/patologia
[Mh] Termos MeSH secundário: Seres Humanos
Patologia Cirúrgica/métodos
Poliestirenos/efeitos adversos
Sequestrantes/efeitos adversos
Sevelamer/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cation Exchange Resins); 0 (Polystyrenes); 0 (Sequestering Agents); 70KO0R01RY (polystyrene sulfonic acid); 9YCX42I8IU (Sevelamer)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE
[do] DOI:10.5858/arpa.2016-0587-RA


  3 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27803462
[Au] Autor:Idota Y; Kogure Y; Kato T; Yano K; Arakawa H; Miyajima C; Kasahara F; Ogihara T
[Ad] Endereço:Faculty of Pharmacy, Takasaki University of Health and Welfare.
[Ti] Título:Relationship between Physical Parameters of Various Metal Ions and Binding Affinity for Alginate.
[So] Source:Biol Pharm Bull;39(11):1893-1896, 2016.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:We investigated the relationship between the physical parameters of various metal ions, including toxic metal ions, and the binding affinity of these metal ions for alginate (Alg). The binding constant, K, of Sr was the highest among all tested metal ions. The order of K values was: Sr >Pb >Tb >Dy >Ca >Cd >Mg >Fe >Fe >Co >Al >Ni >Cs >Cu >Ag >Li >K . The metal ions showing the highest K values had ionic radii within the range of about 90-120 pm. Moreover, the K values of divalent or trivalent metal ions tended to be higher than those of monovalent ions. The number of binding sites per 1 mg of Alg (n) was highest for K , followed by Pb and Cs . The order of affinity (calculated as the product of n and K) was Pb >Dy >Tb >Sr >Ca >Mg >Cd >Fe , Fe >Cs >Al >Co >Ni >Cu >Ag >K >Li . Our results support the idea that Alg would be effective as an excretion accelerator and/or absorption inhibitor for various toxic metal ions.
[Mh] Termos MeSH primário: Alginatos/química
Metais/química
[Mh] Termos MeSH secundário: Sítios de Ligação
Ácido Glucurônico/química
Ácidos Hexurônicos/química
Sequestrantes/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alginates); 0 (Hexuronic Acids); 0 (Metals); 0 (Sequestering Agents); 8A5D83Q4RW (Glucuronic Acid); 8C3Z4148WZ (alginic acid)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170119
[Lr] Data última revisão:
170119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161103
[St] Status:MEDLINE


  4 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27578074
[Au] Autor:Pereira MP; Ständer S
[Ti] Título:Itch Management: Treatments under Development.
[So] Source:Curr Probl Dermatol;50:71-6, 2016.
[Is] ISSN:1662-2944
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Pruritus is a symptom arising from a plethora of dermatological, neurological, and systemic conditions. The pathophysiological mechanisms involved in the transmission of acute and chronic pruritus are of high complexity and not yet fully understood. Recent research has enhanced the understanding of these mechanisms, enabling the development of novel drugs. Specifically, new therapies for inflammatory dermatoses, uremic pruritus, cholestatic pruritus, cutaneous T-cell lymphoma, and prurigo nodularis are being tested in ongoing randomized clinical trials. Compounds in development include neurokinin 1 receptor antagonists, anti-interleukin-31 receptor A antibodies, nerve growth factor inhibitors, transient receptor potential cation channel V1 antagonists, as well as κ-opioid agonists, ileal bile acid transporter inhibitors, and bile acid sequestrants. Effective treatment options for the various forms of chronic pruritus are still insufficient. Basic research studying additional pathophysiological mechanisms involved in pruritus transmission is urgently needed, as well as clinical trials testing new compounds in patients with chronic pruritus. Moreover, clinical trials including specific patients groups, such as pregnant women or children, are of the utmost importance since only few treatment options are currently approved for these patients. The aim of this chapter is to provide an overview of the drugs under development, highlighting the pathophysiological mechanisms they target.
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Antipruriginosos/uso terapêutico
Antagonistas do Receptor de Neuroquinina-1/uso terapêutico
Prurido/tratamento farmacológico
Sequestrantes/uso terapêutico
[Mh] Termos MeSH secundário: Acrilamidas/uso terapêutico
Anticorpos Monoclonais Humanizados/uso terapêutico
Proteínas de Transporte/antagonistas & inibidores
Colestase/complicações
Cloridrato de Colesevelam
Seres Humanos
Linfoma Cutâneo de Células T/complicações
Linfoma Cutâneo de Células T/tratamento farmacológico
Glicoproteínas de Membrana/antagonistas & inibidores
Fator de Crescimento Neural/antagonistas & inibidores
Prurigo/complicações
Prurigo/tratamento farmacológico
Prurido/etiologia
Piridinas/uso terapêutico
Receptores de Interleucina/antagonistas & inibidores
Receptores Opioides kappa/agonistas
Canais de Cátion TRPV/antagonistas & inibidores
Uremia/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acrylamides); 0 (Analgesics, Opioid); 0 (Antibodies, Monoclonal, Humanized); 0 (Antipruritics); 0 (CIM331); 0 (Carrier Proteins); 0 (IL31RA protein, human); 0 (Membrane Glycoproteins); 0 (N-(1-(3,5-difluoro-4-methanesulfonylaminophenyl)ethyl)-3-(2-propyl-6-trifluoromethylpyridine-3-yl)acrylamide); 0 (Neurokinin-1 Receptor Antagonists); 0 (Pyridines); 0 (Receptors, Interleukin); 0 (Receptors, Opioid, kappa); 0 (Sequestering Agents); 0 (TRPV Cation Channels); 0 (bile acid binding proteins); 9061-61-4 (Nerve Growth Factor); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170418
[Lr] Data última revisão:
170418
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160901
[St] Status:MEDLINE
[do] DOI:10.1159/000446046


  5 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27265172
[Au] Autor:Ogunade IM; Arriola KG; Jiang Y; Driver JP; Staples CR; Adesogan AT
[Ad] Endereço:Department of Animal Sciences, Institute of Food and Agricultural Sciences, University of Florida, Gainesville 32611.
[Ti] Título:Effects of 3 sequestering agents on milk aflatoxin M1 concentration and the performance and immune status of dairy cows fed diets artificially contaminated with aflatoxin B1.
[So] Source:J Dairy Sci;99(8):6263-6273, 2016 Aug.
[Is] ISSN:1525-3198
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study examined whether adding 3 mycotoxin-sequestering agents to diets contaminated with aflatoxin B1 (AFB1) would reduce milk aflatoxin M1 (AFM1) concentration, and improve the performance and alter immune status of dairy cows. Fifteen lactating dairy cows were used in an experiment with an incomplete crossover design including four 28-d periods. Treatments included a control diet (C), a toxin diet (T; 1,725µg of AFB1/head per day; 75µg/kg), and diets containing the toxin and 20g/head per day of a proprietary mixture of Saccharomyces cerevisiae fermentation product containing a low (SEQ1) or high (SEQ2) dose of a chlorophyll-based additive, or a low dose of the chlorophyll-based additive and sodium bentonite clay (SEQ3). Sequestering agents were top-dressed on the total mixed ration (TMR) daily in each period, and AFB1 was dosed orally in gelatin capsules before the TMR was fed on d 21 to 25. Milk was sampled twice daily on d 20 to 28 and plasma was sampled on d 20 and 25. Sequestering agents did not affect milk AFM1 concentration during the toxin-dosing period. However, after AFB1 was withdrawn, the sequestering agents reduced the time required (24 vs. 48h) to reduce the milk AFM1 concentration below the Food and Drug Administration action level of 0.5µg/kg. Feeding T instead of C tended to reduce milk and fat-corrected milk yields, but feeding SEQ1 prevented these effects. Red blood cell count and hemoglobin concentration were reduced by feeding T instead of C, but not by feeding SEQ1, SEQ2, or SEQ3. The mean fluorescence intensity of antibody staining for 2 leukocyte adhesion molecules, L-selectin (CD62L) and ß-integrin (CD18), tended to be greatest when SEQ1 and SEQ3 were fed. Plasma acid-soluble protein concentration was decreased by feeding SEQ1, SEQ2, and SEQ3 instead of T. Sequestering agents had no effect on milk AFM1 concentration, but they reduced the time required to reduce milk AFM1 concentration to a safe level after withdrawal of AFB1 from the diet. Only SEQ1 prevented the adverse effects of AFB1 on milk and fat-corrected milk yields.
[Mh] Termos MeSH primário: Aflatoxina B1/análise
Aflatoxina M1/análise
Ração Animal/análise
Dieta/veterinária
Sequestrantes/administração & dosagem
[Mh] Termos MeSH secundário: Ração Animal/microbiologia
Animais
Bentonita/administração & dosagem
Cápsulas
Bovinos
Clorofila/administração & dosagem
Estudos Cross-Over
Relação Dose-Resposta a Droga
Feminino
Fermentação
Contaminação de Alimentos/análise
Microbiologia de Alimentos
Cadeias beta de Integrinas/sangue
Selectina L/sangue
Lactação
Leite/química
Leite/microbiologia
Leite/secreção
Saccharomyces cerevisiae
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Capsules); 0 (Integrin beta Chains); 0 (Sequestering Agents); 126880-86-2 (L-Selectin); 1302-78-9 (Bentonite); 1406-65-1 (Chlorophyll); 6795-23-9 (Aflatoxin M1); 9N2N2Y55MH (Aflatoxin B1)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171021
[Lr] Data última revisão:
171021
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160607
[St] Status:MEDLINE


  6 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26927058
[Au] Autor:Hwang SW; Lee YM; Aldini G; Yeum KJ
[Ad] Endereço:Department of Nano Science & Mechatronics Engineering, College of Science and Technology, Konkuk University, Chungju-si 27478, Korea. swhwang@kku.ac.kr.
[Ti] Título:Targeting Reactive Carbonyl Species with Natural Sequestering Agents.
[So] Source:Molecules;21(3):280, 2016 Feb 27.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Reactive carbonyl species generated by the oxidation of polyunsaturated fatty acids and sugars are highly reactive due to their electrophilic nature, and are able to easily react with the nucleophilic sites of proteins as well as DNA causing cellular dysfunction. Levels of reactive carbonyl species and their reaction products have been reported to be elevated in various chronic diseases, including metabolic disorders and neurodegenerative diseases. In an effort to identify sequestering agents for reactive carbonyl species, various analytical techniques such as spectrophotometry, high performance liquid chromatography, western blot, and mass spectrometry have been utilized. In particular, recent advances using a novel high resolution mass spectrometry approach allows screening of complex mixtures such as natural products for their sequestering ability of reactive carbonyl species. To overcome the limited bioavailability and bioefficacy of natural products, new techniques using nanoparticles and nanocarriers may offer a new attractive strategy for increased in vivo utilization and targeted delivery of bioactives.
[Mh] Termos MeSH primário: Produtos Biológicos/farmacologia
Ácidos Graxos Insaturados/química
Glicosídeos/química
Sequestrantes/farmacologia
[Mh] Termos MeSH secundário: Produtos Biológicos/isolamento & purificação
Cromatografia Líquida de Alta Pressão
Espectrometria de Massas
Nanotecnologia
Oxirredução
Sequestrantes/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Biological Products); 0 (Fatty Acids, Unsaturated); 0 (Glycosides); 0 (Sequestering Agents)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160302
[St] Status:MEDLINE


  7 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26891408
[Au] Autor:Colzani M; De Maddis D; Casali G; Carini M; Vistoli G; Aldini G
[Ad] Endereço:Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli, 25, 20133, Milano, Italy. mara.colzani@unimi.it.
[Ti] Título:Reactivity, Selectivity, and Reaction Mechanisms of Aminoguanidine, Hydralazine, Pyridoxamine, and Carnosine as Sequestering Agents of Reactive Carbonyl Species: A Comparative Study.
[So] Source:ChemMedChem;11(16):1778-89, 2016 Aug 19.
[Is] ISSN:1860-7187
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Reactive carbonyl species (RCS) are endogenous or exogenous byproducts involved in the pathogenic mechanisms of different oxidative-based disorders. Detoxification of RCS by carbonyl quenchers is a promising therapeutic strategy. Among the most studied quenchers are aminoguanidine, hydralazine, pyridoxamine, and carnosine; their quenching activity towards four RCS (4-hydroxy-trans-2-nonenal, methylglyoxal, glyoxal, and malondialdehyde) was herein analyzed and compared. Their ability to prevent protein carbonylation was evaluated in vitro by using an innovative method based on high-resolution mass spectrometry (HRMS). The reactivity of the compounds was RCS dependent: carnosine efficiently quenched 4-hydroxy-trans-2-nonenal, pyridoxamine was particularly active towards malondialdehyde, aminoguanidine was active towards methylglyoxal and glyoxal, and hydralazine efficiently quenched all RCS. Reaction products were generated in vitro and were characterized by HRMS. Molecular modeling studies revealed that the reactivity was controlled by specific stereoelectronic parameters that could be used for the rational design of improved carbonyl quenchers.
[Mh] Termos MeSH primário: Aldeídos/antagonistas & inibidores
Glioxal/antagonistas & inibidores
Malondialdeído/antagonistas & inibidores
Aldeído Pirúvico/antagonistas & inibidores
Sequestrantes/farmacologia
[Mh] Termos MeSH secundário: Carnosina/química
Carnosina/farmacologia
Relação Dose-Resposta a Droga
Guanidinas/química
Guanidinas/farmacologia
Seres Humanos
Hidralazina/química
Hidralazina/farmacologia
Estrutura Molecular
Piridoxamina/química
Piridoxamina/farmacologia
Sequestrantes/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aldehydes); 0 (Guanidines); 0 (Sequestering Agents); 26NAK24LS8 (Hydralazine); 4Y8F71G49Q (Malondialdehyde); 50NP6JJ975 (Glyoxal); 6466NM3W93 (Pyridoxamine); 722KLD7415 (Pyruvaldehyde); 8HO6PVN24W (Carnosine); K1CVM13F96 (4-hydroxy-2-nonenal); SCQ4EZQ113 (pimagedine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160219
[St] Status:MEDLINE
[do] DOI:10.1002/cmdc.201500552


  8 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26859552
[Au] Autor:Spinelli V; Chávez-Talavera O; Tailleux A; Staels B
[Ad] Endereço:aUniv Lille, UMR1011, EGID bInserm, UMR1011 cCHU Lille dInstitut Pasteur de Lille, U1011, Lille, France *Valeria Spinelli and Oscar Chávez-Talavera have contributed equally to the writing of this article.
[Ti] Título:Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors.
[So] Source:Curr Opin Endocrinol Diabetes Obes;23(2):138-44, 2016 Apr.
[Is] ISSN:1752-2978
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE OF REVIEW: This article discusses the impact of bile acid sequestrants (BAS) on cardiovascular risk factors (CVRFs), on the basis of recent (pre)clinical studies assessing the metabolic impact of modulation of enterohepatic bile acid signaling via the bile acid receptors farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5). RECENT FINDINGS: BAS decrease low-density lipoprotein-cholesterol by stimulating de novo hepatic bile acid synthesis and lowering intestinal lipid absorption, and improve glucose homeostasis in type 2 diabetes mellitus, at least in part by increasing GLP-1 production, via intestinal TGR5- and FXR-dependent mechanisms. Intestinal and peripheral FXR and TGR5 modulation also affects peripheral tissues, which can contribute to the reduction of CVRFs. SUMMARY: Bile acids are regulators of metabolism acting in an integrated interorgan manner via FXR and TGR5. Modulation of the bile acid pool size and composition, and selective interference with their receptors could, therefore, be a therapeutic approach to decrease CVRFs. Even though clinical cardiovascular outcome studies using BAS are still lacking, the existing data point to BAS as an efficacious pharmacological approach to reduce CVRFs.
[Mh] Termos MeSH primário: Ácidos e Sais Biliares/metabolismo
Doenças Cardiovasculares/prevenção & controle
Diabetes Mellitus Tipo 2/tratamento farmacológico
Dislipidemias/tratamento farmacológico
Sequestrantes/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Glicemia/efeitos dos fármacos
Glicemia/metabolismo
Doenças Cardiovasculares/etiologia
Doenças Cardiovasculares/metabolismo
Diabetes Mellitus Tipo 2/complicações
Diabetes Mellitus Tipo 2/diagnóstico
Dislipidemias/complicações
Dislipidemias/metabolismo
Seres Humanos
Metabolismo dos Lipídeos/efeitos dos fármacos
Receptores Citoplasmáticos e Nucleares/efeitos dos fármacos
Receptores Citoplasmáticos e Nucleares/metabolismo
Receptores Acoplados a Proteínas-G/efeitos dos fármacos
Receptores Acoplados a Proteínas-G/metabolismo
Medição de Risco
Fatores de Risco
Transdução de Sinais/efeitos dos fármacos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Bile Acids and Salts); 0 (Blood Glucose); 0 (GPBAR1 protein, human); 0 (Receptors, Cytoplasmic and Nuclear); 0 (Receptors, G-Protein-Coupled); 0 (Sequestering Agents); 0 (farnesoid X-activated receptor)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160210
[St] Status:MEDLINE
[do] DOI:10.1097/MED.0000000000000235


  9 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26636406
[Au] Autor:Lin S; Sanders DS; Gleeson JT; Osborne C; Messham L; Kurien M
[Ad] Endereço:aDepartment of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust bDepartment of Infection and Immunity, Academic Unit of Gastroenterology, Medical School, University of Sheffield, Sheffield, UK.
[Ti] Título:Long-term outcomes in patients diagnosed with bile-acid diarrhoea.
[So] Source:Eur J Gastroenterol Hepatol;28(2):240-5, 2016 Feb.
[Is] ISSN:1473-5687
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Bile-acid diarrhoea (BAD) is a recognized cause of chronic diarrhoea; however, its detection remains suboptimal. Currently, there is a paucity of follow-up studies evaluating BAD. This work evaluates the natural history of BAD by examining individuals diagnosed with BAD [7 days of Se-homocholic acid taurine (SeHCAT) retention<10%] and determining the use of and response to bile-acid sequestrants (BAS). MATERIALS AND METHODS: Of the 515 patients, 40% (207/515) who underwent an SeHCAT test at Sheffield Teaching Hospitals (2001-2012) for chronic diarrhoea had BAD. Of the 207 (51%) patients, 107 were diagnosed between 2001 and 2009. In accordance with the guidelines, all of these patients were commenced on BAS. In March 2013, these individuals were reassessed either in the clinic or over the telephone as part of a local service evaluation project. Comparisons were made of both pretreatment and post-treatment variables using a Wilcoxon rank test. RESULTS: Of the 107 patients, 54% (58/107) were followed up, with a median time since diagnosis of 6 years. Among them, 38% were still using BAS at follow-up, with 28% using alternative antidiarrhoeals. The median stool frequency decreased from seven stools per day to three (P=0.0008) in those using BAS. The 34% of patients not receiving treatment had no change in their daily bowel frequency. The main reason for discontinuing treatment was poor tolerability of the BAS (colestyramine/colestipol). CONCLUSION: Our findings indicate that BAD is a chronic condition that best improves with BAS. Consideration should be given to therapeutic options that have a better tolerability profile.
[Mh] Termos MeSH primário: Ácidos e Sais Biliares/metabolismo
Diarreia/etiologia
[Mh] Termos MeSH secundário: Resinas de Troca de Ânions/uso terapêutico
Antidiarreicos/uso terapêutico
Resina de Colestiramina/uso terapêutico
Colestipol/uso terapêutico
Defecação
Técnicas de Diagnóstico do Sistema Digestório
Diarreia/diagnóstico
Diarreia/tratamento farmacológico
Diarreia/metabolismo
Diarreia/fisiopatologia
Substituição de Medicamentos
Inglaterra
Hospitais de Ensino
Seres Humanos
Valor Preditivo dos Testes
Estudos Retrospectivos
Sequestrantes/uso terapêutico
Ácido Taurocólico/administração & dosagem
Ácido Taurocólico/análogos & derivados
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anion Exchange Resins); 0 (Antidiarrheals); 0 (Bile Acids and Salts); 0 (Sequestering Agents); 11041-12-6 (Cholestyramine Resin); 5E090O0G3Z (Taurocholic Acid); 75018-70-1 (23-seleno-25-homotaurocholic acid); K50N755924 (Colestipol)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151223
[Lr] Data última revisão:
151223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151205
[St] Status:MEDLINE
[do] DOI:10.1097/MEG.0000000000000541


  10 / 31 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26525925
[Au] Autor:Philpott H; Nandurkar S; Lubel J; Gibson PR
[Ad] Endereço:Hamish Philpott, Sanjay Nandurkar, John Lubel, Peter R Gibson, Monash University, Eastern Health, The Alfred Hospital, Melbourne 3128, Australia.
[Ti] Título:Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome.
[So] Source:World J Gastroenterol;21(40):11379-86, 2015 Oct 28.
[Is] ISSN:2219-2840
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Patients presenting with abdominal pain and diarrhea are often labelled as suffering from irritable bowel syndrome, and medications may be used often without success. Advances in the understanding of the causes of the symptoms (including pelvic floor weakness and incontinence, bile salt malabsorption and food intolerance) mean that effective, safe and well tolerated treatments are now available.
[Mh] Termos MeSH primário: Ácidos e Sais Biliares/metabolismo
Dieta com Restrição de Carboidratos
Carboidratos da Dieta/efeitos adversos
Fibras na Dieta/administração & dosagem
Intestinos/fisiopatologia
Síndrome do Intestino Irritável/terapia
Síndromes de Malabsorção/terapia
Diafragma da Pelve/fisiopatologia
Sequestrantes/uso terapêutico
[Mh] Termos MeSH secundário: Dor Abdominal/fisiopatologia
Dor Abdominal/terapia
Diarreia/fisiopatologia
Diarreia/terapia
Dieta com Restrição de Carboidratos/economia
Carboidratos da Dieta/metabolismo
Fibras na Dieta/economia
Fibras na Dieta/metabolismo
Incontinência Fecal/fisiopatologia
Incontinência Fecal/terapia
Custos de Cuidados de Saúde
Seres Humanos
Absorção Intestinal
Intestinos/metabolismo
Síndrome do Intestino Irritável/economia
Síndrome do Intestino Irritável/metabolismo
Síndrome do Intestino Irritável/fisiopatologia
Síndromes de Malabsorção/economia
Síndromes de Malabsorção/metabolismo
Síndromes de Malabsorção/fisiopatologia
Sequestrantes/economia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Bile Acids and Salts); 0 (Dietary Carbohydrates); 0 (Dietary Fiber); 0 (Sequestering Agents)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151104
[St] Status:MEDLINE
[do] DOI:10.3748/wjg.v21.i40.11379



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde